222 related articles for article (PubMed ID: 17896924)
1. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer.
Wang Y; Kreisberg JI; Ghosh PM
Curr Cancer Drug Targets; 2007 Sep; 7(6):591-604. PubMed ID: 17896924
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
3. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.
Sharma M; Chuang WW; Sun Z
J Biol Chem; 2002 Aug; 277(34):30935-41. PubMed ID: 12063252
[TBL] [Abstract][Full Text] [Related]
5. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
6. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer.
Liao X; Thrasher JB; Holzbeierlein J; Stanley S; Li B
Endocrinology; 2004 Jun; 145(6):2941-9. PubMed ID: 14988390
[TBL] [Abstract][Full Text] [Related]
7. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Benitez DA; Pozo-Guisado E; Clementi M; Castellón E; Fernandez-Salguero PM
Br J Cancer; 2007 May; 96(10):1595-604. PubMed ID: 17486135
[TBL] [Abstract][Full Text] [Related]
8. Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways.
Górowska-Wójtowicz E; Hejmej A; Kamińska A; Pardyak L; Kotula-Balak M; Dulińska-Litewka J; Laidler P; Bilińska B
Toxicol In Vitro; 2017 Apr; 40():324-335. PubMed ID: 28163245
[TBL] [Abstract][Full Text] [Related]
9. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
10. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
Dulinska-Litewka J; McCubrey JA; Laidler P
Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
[TBL] [Abstract][Full Text] [Related]
11. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
12. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways.
Hu Y; Sun H; Owens RT; Wu J; Chen YQ; Berquin IM; Perry D; O'Flaherty JT; Edwards IJ
Neoplasia; 2009 Oct; 11(10):1042-53. PubMed ID: 19794963
[TBL] [Abstract][Full Text] [Related]
13. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.
Chesire DR; Ewing CM; Gage WR; Isaacs WB
Oncogene; 2002 Apr; 21(17):2679-94. PubMed ID: 11965541
[TBL] [Abstract][Full Text] [Related]
14. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
Chatterjee B
Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
[TBL] [Abstract][Full Text] [Related]
15. Akt in prostate cancer: possible role in androgen-independence.
Ghosh PM; Malik S; Bedolla R; Kreisberg JI
Curr Drug Metab; 2003 Dec; 4(6):487-96. PubMed ID: 14683476
[TBL] [Abstract][Full Text] [Related]
16. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
17. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway.
Liu S; Vinall RL; Tepper C; Shi XB; Xue LR; Ma AH; Wang LY; Fitzgerald LD; Wu Z; Gandour-Edwards R; deVere White RW; Kung HJ
Oncogene; 2008 Jan; 27(4):499-505. PubMed ID: 17653089
[TBL] [Abstract][Full Text] [Related]
18. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.
Deep G; Oberlies NH; Kroll DJ; Agarwal R
Oncogene; 2008 Jun; 27(28):3986-98. PubMed ID: 18332867
[TBL] [Abstract][Full Text] [Related]
19. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
Terry S; Yang X; Chen MW; Vacherot F; Buttyan R
J Cell Biochem; 2006 Oct; 99(2):402-10. PubMed ID: 16741972
[TBL] [Abstract][Full Text] [Related]
20. Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells.
Lee SH; Johnson D; Luong R; Sun Z
J Biol Chem; 2015 Jan; 290(5):2759-68. PubMed ID: 25527506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]